BACKGROUND: The common exon 3 deletion polymorphism of the growth hormone receptor (d3-GHR) is associated with disease severity in acromegaly patients. The GHR antagonist pegvisomant (PEGV) is highly effective in treating severe acromegaly. Response to PEGV treatment seems to be influenced by d3-GHR and appears to be more responsive to PEGV, although available results remain conflicting. OBJECTIVE: To assess the influence of d3-GHR on the responsiveness of acromegaly patients to PEGV by compiling the evidence derived from the largest available studies. DESIGN: A systematic review of the literature identified three published studies and one conference abstract. Acromegaly patients (n = 324, 49.7% d3-GHR carriers) were treated with either PEGV monotherapy or PEGV combined with long-acting somatostatin analogues and/or cabergoline. A meta-analysis of raw data from these studies was performed. RESULTS: No significant effect of the d3-GHR was observed while bringing insulin-like growth factor I (IGF-I) levels below the upper limit of normal with PEGV, which was defined as the lowest IGF-I level during PEGV treatment (mean difference: -2.3%; 95% CI: -6.5 to 1.8, p = 0.270). The PEGV dose required to achieve the lowest IGF-I levels was also not significantly influenced by individuals carrying d3-GHR (mean difference: 4.1 mg weekly; 95% CI: -5.1 to 13.2, p = 0.385). For both outcomes, separate analysis of PEGV monotherapy and combination treatment gave similar results. CONCLUSION: Our findings suggest that the d3-GHR polymorphism has no effect on biochemical disease control in acromegaly, as it is not of added value for either the prediction of PEGV responsiveness or the determination of the required PEGV dose.
BACKGROUND: The common exon 3 deletion polymorphism of the growth hormone receptor (d3-GHR) is associated with disease severity in acromegalypatients. The GHR antagonist pegvisomant (PEGV) is highly effective in treating severe acromegaly. Response to PEGV treatment seems to be influenced by d3-GHR and appears to be more responsive to PEGV, although available results remain conflicting. OBJECTIVE: To assess the influence of d3-GHR on the responsiveness of acromegalypatients to PEGV by compiling the evidence derived from the largest available studies. DESIGN: A systematic review of the literature identified three published studies and one conference abstract. Acromegalypatients (n = 324, 49.7% d3-GHR carriers) were treated with either PEGV monotherapy or PEGV combined with long-acting somatostatin analogues and/or cabergoline. A meta-analysis of raw data from these studies was performed. RESULTS: No significant effect of the d3-GHR was observed while bringing insulin-like growth factor I (IGF-I) levels below the upper limit of normal with PEGV, which was defined as the lowest IGF-I level during PEGV treatment (mean difference: -2.3%; 95% CI: -6.5 to 1.8, p = 0.270). The PEGV dose required to achieve the lowest IGF-I levels was also not significantly influenced by individuals carrying d3-GHR (mean difference: 4.1 mg weekly; 95% CI: -5.1 to 13.2, p = 0.385). For both outcomes, separate analysis of PEGV monotherapy and combination treatment gave similar results. CONCLUSION: Our findings suggest that the d3-GHR polymorphism has no effect on biochemical disease control in acromegaly, as it is not of added value for either the prediction of PEGV responsiveness or the determination of the required PEGV dose.
Authors: M Filopanti; L Olgiati; G Mantovani; S Corbetta; M Arosio; V Gasco; L De Marinis; C Martini; F Bogazzi; S Cannavò; A Colao; D Ferone; G Arnaldi; F Pigliaru; A Peri; G Angeletti; M L Jaffrain-Rea; A G Lania; A Spada Journal: J Clin Endocrinol Metab Date: 2011-12-07 Impact factor: 5.958
Authors: Fan Liu; A Emile J Hendriks; Arwin Ralf; Annemieke M Boot; Emelie Benyi; Lars Sävendahl; Ben A Oostra; Cornelia van Duijn; Albert Hofman; Fernando Rivadeneira; André G Uitterlinden; Stenvert L S Drop; Manfred Kayser Journal: Hum Genet Date: 2013-11-20 Impact factor: 4.132
Authors: Laura Montefusco; Marcello Filopanti; Cristina L Ronchi; Luca Olgiati; Carmen La-Porta; Marco Losa; Paolo Epaminonda; Francesca Coletti; Paolo Beck-Peccoz; Anna Spada; Andrea G Lania; Maura Arosio Journal: Clin Endocrinol (Oxf) Date: 2010-05 Impact factor: 3.478
Authors: Antonio Bianchi; Gherardo Mazziotti; Laura Tilaro; Vincenzo Cimino; Flora Veltri; Eleonora Gaetani; Giovanni Pecorini; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis Journal: Pituitary Date: 2009 Impact factor: 4.107
Authors: Peter Kamenicky; Christine Dos Santos; Consuelo Espinosa; Sylvie Salenave; Françoise Galland; Yves Le Bouc; Patrick Maison; Pierre Bougnères; Philippe Chanson Journal: Eur J Endocrinol Date: 2009-05-13 Impact factor: 6.664
Authors: M J E Wassenaar; O M Dekkers; A M Pereira; J M Wit; J W Smit; N R Biermasz; J A Romijn Journal: J Clin Endocrinol Metab Date: 2009-07-07 Impact factor: 5.958
Authors: S E Franck; A J van der Lely; P J D Delhanty; J O L Jørgensen; S J C M M Neggers Journal: Eur J Endocrinol Date: 2015-08-04 Impact factor: 6.664
Authors: J Pontes; M Madeira; C H A Lima; L L Ogino; F de Paula Paranhos Neto; L M C de Mendonça; M L F Farias; L Kasuki; M R Gadelha Journal: J Endocrinol Invest Date: 2019-08-07 Impact factor: 4.256
Authors: A Giustina; G Arnaldi; F Bogazzi; S Cannavò; A Colao; L De Marinis; E De Menis; E Degli Uberti; F Giorgino; S Grottoli; A G Lania; P Maffei; R Pivonello; E Ghigo Journal: J Endocrinol Invest Date: 2017-02-07 Impact factor: 4.256